Introduction: Patients with early HER2-positive breast cancer (BC) benefit from HER2-targeted systemic therapy. The endorsed standard adjuvant treatment for patients with early HER2-positive breast cancer is chemotherapy plus trastuzumab administered for 1 year. Areas covered: Several trials have investigated modifications of the standard treatment in terms of de-escalation by either shortening the duration or giving less resource-demanding regimens and in terms of escalation by either adding a second anti-HER2 agent or extending the duration of HER2-targeted treatment for more than 12 months. In this perspective, we would offer a comprehensive view of these trials and discuss their findings. Expert commentary: At the current state of knowledge, there are still open questions regarding the management of HER2+ BC patients, such as the most adequate duration of trastuzumab therapy, the optimal chemotherapy regimen that should be combined with trastuzumab, and the addition of a second anti-HER2 agent. Growing evidences suggest that some HER2+ BC patients may not need chemotherapy. If these patients could be recognized upfront, optimal response could potentially be reached with HER2-targeted therapy alone.
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer / A. Esposito, G. Viale, C. Criscitiello, G. Curigliano. - In: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. - ISSN 1751-2433. - 12:1(2019 Jan 02), pp. 9-16.
|Titolo:||A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer|
VIALE, GIULIA (Secondo)
CURIGLIANO, GIUSEPPE (Ultimo) [Writing – Original Draft Preparation] (Corresponding)
|Parole Chiave:||Adjuvant trastuzumab duration; breast cancer; HER2-positive breast cancer; HER2-targeted therapy; Pharmacology, Toxicology and Pharmaceutics (all); Pharmacology (medical)|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||2-gen-2019|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1080/17512433.2019.1552134|
|Appare nelle tipologie:||01 - Articolo su periodico|